Campaigners say US govt should have remdesivir patent rights

The PrEP4All campaign has argued that the US government should own joint patent rights for remdesivir, the Gilead Sciences antiviral which is the only drug approved anywhere for treating COVID-19.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

The curious case of Wuhan’s Institute of Virology and remdesivir

20 April 2021 Changes to China’s patent laws and a filing by a Wuhan lab involving Gilead’s remdesivir have set up an interesting patent race, says Thomas Moga of Dykema.

Americas

Gilead accuses Floridian clinics of HIV drug fraud

4 November 2020 Gilead Sciences has claimed that a group of Florida-based healthcare clinics, pharmacies, and lab testing facilities have “wrongfully captured tens of millions of dollars” through a fraudulent programme.

More on this story

Biotechnology

The curious case of Wuhan’s Institute of Virology and remdesivir

20 April 2021 Changes to China’s patent laws and a filing by a Wuhan lab involving Gilead’s remdesivir have set up an interesting patent race, says Thomas Moga of Dykema.

Americas

Gilead accuses Floridian clinics of HIV drug fraud

More on this story

Biotechnology

The curious case of Wuhan’s Institute of Virology and remdesivir

20 April 2021 Changes to China’s patent laws and a filing by a Wuhan lab involving Gilead’s remdesivir have set up an interesting patent race, says Thomas Moga of Dykema.

Americas

Gilead accuses Floridian clinics of HIV drug fraud